论文部分内容阅读
目的探讨卵巢肿瘤患者血浆溶血磷脂酸(lysophosphatidic acid,LPA)水平及其受体Edg-4在卵巢肿瘤组织中的表达情况。方法2002-01-2004-01扬州大学临床医学院测定57例卵巢恶性肿瘤患者、66例卵巢良性肿瘤患者及37例健康对照者血浆LPA水平和血清CA125水平,比较两者在诊断卵巢恶性肿瘤中的敏感性和特异性。并用RT-PCR方法检测其中18例卵巢恶性肿瘤患者及24例卵巢良性肿瘤患者肿瘤组织Edg-4mRNA的表达情况。结果卵巢恶性肿瘤患者、卵巢良性肿瘤患者及健康对照者血浆LPA水平分别为(5.63±2.35)μmol/L、(2.80±1.13)μmol/L、(2.51±1.08)μmol/L,前者血浆LPA水平与后两者相比,差异有统计学意义(P<0.01);后两者之间血浆LPA水平差异无统计学意义(P>0.05)。LPA和CA125在诊断卵巢恶性肿瘤的敏感性和特异性方面差异无统计学意义(P>0.05)。18例卵巢恶性肿瘤患者肿瘤组织中有16例Edg-4mRNA表达阳性,24例卵巢良性肿瘤患者肿瘤组织中有11例Edg-4mRNA表达阳性,两者在Edg-4mRNA表达方面差异有统计学意义(P<0.01)。结论卵巢恶性肿瘤患者血浆LPA水平明显高于良性肿瘤患者和健康对照者;大多数卵巢恶性肿瘤患者表达Edg-4受体,部分卵巢良性肿瘤患者表达Edg-4受体,血浆LPA及其受体Edg-4可能成为治疗卵巢恶性肿瘤的新靶点。
Objective To investigate the plasma levels of lysophosphatidic acid (LPA) and its receptor Edg-4 in ovarian tumors in patients with ovarian tumors. Methods A total of 57 patients with ovarian cancer, 66 patients with benign ovarian tumors and 37 healthy controls were enrolled in this study. The plasma LPA levels and serum CA125 levels were measured in the clinical diagnosis of ovarian cancer from 2002-01-2004-01. Sensitivity and specificity. RT-PCR was used to detect the expression of Edg-4mRNA in 18 cases of ovarian cancer and 24 cases of ovarian benign tumor. Results The plasma levels of LPA in ovarian cancer patients, benign ovarian tumor patients and healthy controls were (5.63 ± 2.35) μmol / L, (2.80 ± 1.13) μmol / L and (2.51 ± 1.08) μmol / Compared with the latter two groups, the difference was statistically significant (P <0.01). There was no significant difference in plasma LPA levels between the latter two groups (P> 0.05). There was no significant difference in the sensitivity and specificity of LPA and CA125 in the diagnosis of ovarian cancer (P> 0.05). Edg-4 mRNA expression was positive in 16 of 18 ovarian cancer patients and Edg-4 mRNA in 11 of 24 benign ovarian tumor patients. The difference of Edg-4 mRNA expression between the two groups was statistically significant ( P <0.01). Conclusions Plasma LPA levels in patients with ovarian cancer are significantly higher than those in benign and healthy controls. Edg-4 receptor is expressed in most ovarian cancer patients. Edg-4 receptor, plasma LPA and its receptor Edg-4 may be a new target for the treatment of ovarian malignancies.